A genuinely important development appeared in the clinical-trial registry September 25, 2026. A new study called CHAMP (NCT07842965) will evaluate leronlimab in colorectal-cancer patients with liver metastases. It is a Phase 1/1b study sponsored by City of Hope, with the National Cancer Institute listed as a collaborator, and Dr. Pashtoon Kasi as principal investigator. Target enrollment is 36 patients. Syfrah
https://clinicaltrials.gov/study/NCT07842965?...hatgpt.com